Skip to main content
. 2023 Apr 17;12(8):e028534. doi: 10.1161/JAHA.122.028534

Figure 1. Graphical overview of SCAN‐MP design.

Figure 1

Assessments are performed at baseline for all participants, and again at 6‐ and 12 months for those with a Tc‐99m‐PYP scan diagnostic of ATTR‐CM and for all with the pV142I variant irrespective of Tc‐99m‐PYP scan result. Tc‐99m‐PYP scan, TTR genotype, and genetic ancestry analysis are performed at baseline only. ATTR‐CM indicates transthyretin amyloid cardiomyopathy; ATTRv, transthyretin amyloidosis owing to any transthyretin gene variant; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular; LVEF, left ventricular ejection fraction; RBP4, retinol binding protein–4; SCAN‐MP, Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations; SF‐12, Short Form–12; Tc‐99m‐PYP, technetium‐99m‐pyrophosphate; and TTR, transthyretin. Created with BioRender.com.